# bioAffinity Technologies, Inc. (BIAFW) — capital_raise/atm_program [announced]
Source: sec.gov · situation sit_a78a2a6521a4d9d4cbb3 · public 4939079108284342998 · retrieved 2026-08-19T12:00:35.897Z

## Overview
bioAffinity Technologies, Inc. is a commercial physical and biological research services company.

On August 12, 2026, bioAffinity Technologies, Inc. entered into a securities purchase agreement with an institutional investor for a private placement that closed on August 14, 2026. The offering consisted of pre-funded warrants at $0.4657 per warrant to purchase 8,462,027 shares, Series A warrants to purchase 8,462,027 shares, and Series B warrants to purchase 8,462,027 shares, each with an exercise price of $0.4727 per share. The Series A and Series B Warrants are exercisable following stockholder approval and expire five years after issuance. The company received net proceeds of approximately $3.6 million after deducting placement agent fees and offering expenses, which it intends to use for working capital and general corporate purposes.

## Terms
- Counterparty: Institutional investor · Deal value: $3.6M · Consideration: cash · Price/share: $0.4657

## Key dates
- Announced 2026-08-14

## Timeline
- 2026-08-14 · 8-K (0001493152-26-038437): 8-K - bioAffinity Technologies, Inc. — *bioAffinity Technologies, Inc. is a commercial physical and biological research services company.* On August 12, 2026, bioAffinity Technologies, Inc. entered into a securities purchase agreement with an institutional investor for a private placement that closed on August 14, 2026. The offering consisted of pre-funded warrants at $0.4657 per warrant to purchase 8,462,027 shares, Series A warrants to purchase 8,462,027 shares, and Series B warrants to purchase 8,462,027 shares, each with an exercise price of $0.4727 per share. The Series A and Series B Warrants are exercisable following stockholder approval and expire five years after issuance. The company received net proceeds of approximately $3.6 million after deducting placement agent fees and offering expenses, which it intends to use for working capital and general corporate purposes.
  https://www.sec.gov/Archives/edgar/data/1712762/0001493152-26-038437.txt

## Citations
- 0001493152-26-038437 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226038437